Stenoparib is under clinical development by Allarity Therapeutics and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Stenoparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Stenoparib overview
It was also under development for endometrial cancer, diffuse large B-cell lymphoma, and pediatric tumors (renal tumors), triple negative breast cancer, metastatic ovarian cancer, melanoma, B-cell chronic lymphocytic leukemia, follicular lymphoma, marginal zone B-cell lymphoma, mantle cell lymphoma, pancreatic cancer, lung cancer and malignant mesothelioma. It is being developed based on DRP platform. It was also under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Allarity Therapeutics overview
Allarity Therapeutics (Allarity) is a clinical-stage precision medicine company that develops drugs for cancer. The company’s lead candidate is stenoparib, a dual PARP and Tankyrase inhibitor against ovarian cancer. Allarity utilizes its proprietary drug response predictor (DRP) diagnostic platform technology that models human tumor biology and predicts cancer patient response which is used to refine patient selection and improve clinical outcomes.. The company operates in Denmark and the US. Allarity is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Stenoparib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
